Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (1y) (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 61.90% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -22.14% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 0.46% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 125.00% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 425.00% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -267.74% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -18.09% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.33% |
| 10 | Kiniksa Pharmaceuticals International | 3.73 Bn | 3.26 Bn | 193.47 Mn | 124.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.87% |
| Dec 31, 2025 | 187.13% |
| Sep 30, 2025 | 1,606.13% |
| Jun 30, 2025 | 443.54% |
| Mar 31, 2025 | 459.92% |
| Dec 31, 2024 | 333.99% |
| Sep 30, 2024 | -113.16% |
| Jun 30, 2024 | 238.07% |
| Mar 31, 2024 | 193.44% |
| Dec 31, 2023 | 137.36% |
| Sep 30, 2023 | -72.63% |
| Jun 30, 2023 | 52.16% |
| Mar 31, 2023 | 88.42% |
| Dec 31, 2022 | 38.70% |
| Sep 30, 2022 | 317.66% |
| Jun 30, 2022 | 79.83% |
| Mar 31, 2022 | 8.17% |
| Dec 31, 2021 | 54.16% |
| Sep 30, 2021 | 16.93% |
| Jun 30, 2021 | -32.71% |